Vir Biotechnology Valuation
| VIR Stock | USD 7.12 0.17 2.45% |
At this time, the company appears to be undervalued. Vir Biotechnology has a current Real Value of $13.24 per share. The regular price of the company is $7.12. Our model measures the value of Vir Biotechnology from inspecting the company fundamentals such as Return On Equity of -0.37, current valuation of 178.91 M, and Shares Owned By Insiders of 11.90 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Vir Biotechnology's valuation include:
Price Book 0.7903 | Enterprise Value 178.9 M | Enterprise Value Ebitda 0.8951 | Price Sales 12.4725 | Forward PE 4.3611 |
Undervalued
Today
Please note that Vir Biotechnology's price fluctuation is somewhat reliable at this time. Calculation of the real value of Vir Biotechnology is based on 3 months time horizon. Increasing Vir Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Vir stock is determined by what a typical buyer is willing to pay for full or partial control of Vir Biotechnology. Since Vir Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vir Stock. However, Vir Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.12 | Real 13.24 | Target 32.75 | Hype 7.09 | Naive 5.21 |
The intrinsic value of Vir Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vir Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vir Biotechnology helps investors to forecast how Vir stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vir Biotechnology more accurately as focusing exclusively on Vir Biotechnology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Vir Biotechnology's intrinsic value based on its ongoing forecasts of Vir Biotechnology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Vir Biotechnology's closest peers.
Vir Biotechnology Cash |
|
Vir Valuation Trend
Vir Biotechnology's real value is important for investors to make better decisions and a more accurate overall view of Vir Biotechnology's financial worth over time. Using both Vir Biotechnology's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Vir Revenue by Product
Vir Biotechnology Total Value Analysis
Vir Biotechnology is at this time forecasted to have company total value of 178.91 M with market capitalization of 980.57 M, debt of 124.54 M, and cash on hands of 2.2 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Vir Biotechnology fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
178.91 M | 980.57 M | 124.54 M | 2.2 B |
Vir Biotechnology Investor Information
About 74.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.79. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vir Biotechnology has Price/Earnings To Growth (PEG) ratio of 1.14. The entity recorded a loss per share of 3.93. The firm had not issued any dividends in recent years. Based on the key measurements obtained from Vir Biotechnology's financial statements, Vir Biotechnology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Vir Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vir Biotechnology has an asset utilization ratio of 4.49 percent. This connotes that the Company is making $0.0449 for each dollar of assets. An increasing asset utilization means that Vir Biotechnology is more efficient with each dollar of assets it utilizes for everyday operations.Vir Biotechnology Ownership Allocation
Vir Biotechnology shows a total of 137.72 Million outstanding shares. The majority of Vir Biotechnology outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vir Biotechnology to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vir Biotechnology. Please pay attention to any change in the institutional holdings of Vir Biotechnology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vir Biotechnology Profitability Analysis
The company reported the last year's revenue of 86.18 M. Reported Net Loss for the year was (615.06 M) with profit before taxes, overhead, and interest of 1.03 B.About Vir Biotechnology Valuation
The stock valuation mechanism determines Vir Biotechnology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Vir Biotechnology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vir Biotechnology. We calculate exposure to Vir Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vir Biotechnology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 83.4 M | 79.2 M | |
| Pretax Profit Margin | (7.29) | (7.65) | |
| Operating Profit Margin | (7.94) | (8.34) | |
| Net Loss | (7.14) | (7.49) | |
| Gross Profit Margin | 0.97 | 1.02 |
Vir Biotechnology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Vir Biotechnology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 134.1 M | |
| Quarterly Earnings Growth Y O Y | 0.585 | |
| Forward Price Earnings | 4.3611 |
Vir Biotechnology Current Valuation Indicators
Vir Biotechnology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Vir Biotechnology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Vir Biotechnology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Vir Biotechnology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Vir Biotechnology's worth.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.